secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-269486
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr reports Q3 results; Phase 3 efzofitimod miss but plans FDA meeting
-----------------------------------------------------------------------

- Phase 3 EFZO-FIT missed primary endpoint of corticosteroid dose reduction at week 48; 5.0 mg/kg showed benefit on multiple quality-of-life measures.
- Company plans FDA meeting in Q1 2026 to discuss path forward for efzofitimod in pulmonary sarcoidosis.
- Phase 2 EFZO-CONNECT enrollment in SSc-ILD expected to complete H1 2026; interim data reported Q2 2025.
- Cash, equivalents, restricted cash and investments $92.9M as of Sep 30, 2025.
- R&D expenses $22.1M, G&A $4.8M for Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000119312525269486/0001193125-25-269486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000119312525269486/atyr-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-269486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer